{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/68beeb540e15f0d455abc0b7/69974a1c7012ce5376ac59bc?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Acute promyelocytic leukaemia (2025 update including APOLLO trial and UK approvals)","description":"<p>An audio summary of the management of APML, updated with new findings from the APOLLO trial (UK landscape)</p><p><br></p><ul><li><a href=\"https://ashpublications.org/blood/article/133/15/1630/273295/Management-of-acute-promyelocytic-leukemia-updated\" rel=\"noopener noreferrer\" target=\"_blank\">Sanz et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet</a></li><li><a href=\"https://www.england.nhs.uk/wp-content/uploads/2025/02/commissioning-policy-2320-arsenic-trioxide-acute-promyelocytic-leukaemia.pdf\" rel=\"noopener noreferrer\" target=\"_blank\">NHS England Clinical Commissioning Policy: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)</a></li></ul>","author_name":"Richard Buka"}